The DOI matches its Crossref record.
Treatment of latent tuberculosis infection: An update
Abstract
Isoniazid (INH) has been the mainstay of treatment of latent tuberculosis infection for almost 50 years. The currently recommended preferred regimen is 9 months daily self‐administered INH (9H); this has efficacy of more than 90% if completed properly. Unfortunately, INH is associated with serious adverse events, including hepatotoxicity. Although risk factors for this complication are well established, allowing for better selection of candidates for therapy, this complication still occurs, and is occasionally fatal. Hence close follow up of patients is necessary, increasing the cost and complexity of treatment. This problem, plus the lengthy duration, results in poor acceptance by patients and providers, and poor adherence by patients. As a result, many preventable cases of tuberculosis continue to occur, and the public health impact of latent tuberculosis infection treatment is suboptimal. These problems have spurred interest in finding shorter, safer and cheaper alternative regimens, with similar efficacy. Of the many regimens that have been examined, 2 months of rifampin and pyrazinamide has excellent efficacy—in experimental studies in mice and randomized trials, largely in HIV‐infected persons. However, while the safety of 2 months of rifampin and pyrazinamide appears acceptable in HIV‐infected persons and children, in non‐HIV‐infected adults this regimen is associated with an unacceptably high rate of severe liver toxicity. Three to four months of INH and rifampin has had equivalent effectiveness as 6 months INH in several randomized trials. However, completion of therapy and toxicity has been the same as with INH—possibly because two drugs are taken rather than one. The fourth commonly studied regimen is 4 months rifampin. This has been found to have significantly better completion than 9H, with significantly less toxicity, especially hepatotoxicity. However, only one trial has evaluated efficacy and effectiveness of mono‐rifampin therapy. In this trial, 3 months rifampin had somewhat better efficacy than either 3 months of isoniazid and rifampin (3HR) or 6 months isoniazid. Two large scale trials are ongoing; one is comparing efficacy and effectiveness of 9H with 4 months rifampin (both daily and self‐administered), while the second, which is nearing completion, compares daily self‐administered 9H with 3 months directly observed once weekly INH combined with rifapentine. The results of these two trials will likely shape future recommendations substantially.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992
Self-citationGetahun, H., Matteelli, A., Abubakar, I., Aziz, M. A., Baddeley, A., Barreira, D., Den Boon, S., Borroto Gutierrez, S. M., Bruchfeld, J., Burhan, E., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01245-2015 · Cited by 596
Self-citationAnti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
Latent tuberculosis infection: An overview
Kiazyk, S., & Ball, T. (2017) · Canada Communicable Disease Report · doi:10.14745/ccdr.v43i34a01 · Cited by 266
Teste tuberculínico: pesquisa operacional no Mato Grosso do Sul
Oliveira, S. M. D. V. L. D., Ruffino-Netto, A., Paniago, A. M. M., Oliveira, O. A. D., Marques, M., Cunha, R. V. D., & Andreotti, R. (2011) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132011000500012 · Cited by 6
Metadata
- Authors
- LOBUE, P., & MENZIES, D.
- Venue
- Respirology
- Publisher
- Wiley
- Published
- 2010-04-28
- Volume
- 15
- Issue
- 4
- Pages
- 603-622
- ISSN
- 1323-7799 (ISSN-L)
- 1440-1843
- OpenAlex
- W1672832385
- Cited by
- 190
- References
- 0
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of latent tuberculosis infection: An update. https://app.cochat.ai/papers/10.1111/j.1440-1843.2010.01751.x
- The paper
- LOBUE, P., & MENZIES, D. (2010). Treatment of latent tuberculosis infection: An update. Respirology. https://doi.org/10.1111/j.1440-1843.2010.01751.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.